title: Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia in Adults.
abstract: The majority of adults with acute lymphoblastic leukemia will achieve a first complete remission (CR). However relapse is the most common cause of treatment failure. Outcomes after relapse remain poor, with long-term survival in the order of 10 %. Treatment decisions made at the time of first complete remission are thus critical to ensuring long-term survival. Allogeneic hematopoietic cell transplant (HCT) is effective at preventing relapse in many transplant recipients but is also associated with significant treatment related morbidity and mortality. Alternatively, ongoing systemic chemotherapy offers lower toxicity at the expense of increased relapse rates. Over the past decades, both the safety of transplant and the efficacy of non-transplant chemotherapy have improved. Emerging data show substantially improved outcomes for young adults treated with pediatric-inspired chemotherapy regimens that question the role of HCT in the upfront setting. In this review, we review the data supporting the role of allogeneic transplantation in adult acute lymphoblastic leukemia (ALL), and we propose a therapeutic algorithm for upfront therapy of adults with ALL.
authors.affiliation: Section of Hematology/Oncology, Department of Internal Medicine, University of Manitoba, Winnipeg, MB, Canada.
authors.forename: Craig
authors.initials: C
authors.lastname: Speziali
authors.affiliation: Section of Hematology/Oncology, Department of Internal Medicine, University of Manitoba, Winnipeg, MB, Canada.|Department of Medical Oncology and Haematology, CancerCare Manitoba, 675 McDermott Avenue, Winnipeg, MB, R3E 0V9, Canada.
authors.forename: Kristjan
authors.initials: K
authors.lastname: Paulson
authors.affiliation: Section of Hematology/Oncology, Department of Internal Medicine, University of Manitoba, Winnipeg, MB, Canada. mseftel@cancercare.mb.ca.|Department of Medical Oncology and Haematology, CancerCare Manitoba, 675 McDermott Avenue, Winnipeg, MB, R3E 0V9, Canada. mseftel@cancercare.mb.ca.
authors.forename: Matthew
authors.initials: M
authors.lastname: Seftel
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007167:Immunotherapy; D018365:Neoplasm, Residual; D010677:Philadelphia Chromosome; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000473:pathology / Q000628:therapy*; D012074:Remission Induction; D014184:Transplantation, Homologous
chemical_list: D000911:Antibodies, Monoclonal
keywords: Acute lymphoblastic leukemia; Adults; Hematopoietic cell transplantation